Co formulated with Emtricitabine and tenofovir as ATRIPLA
Rash, usually in the first 2 weeks, is the most common side-effect; discontinue if severe rash/stephens johnson syndrome with blistering, desquamation, mucosal involvement or fever.
if rash mild or moderate, may continue without interruption—usually resolves within 1 month
Abnormal dreams , sleep disturbance fatigue and impaired concentration.
Patients or their carers should be advised to seek immediate medical attention if symptoms such as severe depression, psychosis or suicidal ideation occur
efavirenz has many drug interactions
see drug interaction app
can cause hepatitis monitor liver function; avoid in moderate to severe impairment; greater risk of hepatic side-effects in chronic hepatitis B or C
FDA category D
The APR provides the best data on teratogenicity and first trimester antiretroviral therapy exposure. There are now more than 200 prospective reports of first-trimester exposure to Efavirenz with no signal of increased risk
Indicated as prefered first line third agent an antiretroviral treatment guidelines